Vident Advisory’s GSK GSK Stock Holding History

Vident Advisory’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.04M	Buy	36,983 +9,064	+32%	+$491K	0.02%	620
2025 Q4	$1.37M	Buy	27,919 +689	+3%	+$32.1K	0.01%	690
2025 Q3	$1.18M	Sell	27,230 -287	-1%	-$11.2K	0.01%	752
2025 Q2	$1.06M	Sell	27,517 -857	-3%	-$32.7K	0.01%	716
2025 Q1	$1.1M	Buy	28,374 +8,294	+41%	+$304K	0.02%	691
2024 Q4	$679K	Buy	20,080 +813	+4%	+$29.3K	0.01%	811
2024 Q3	$788K	Buy	19,267 +1,735	+10%	+$71K	0.02%	722
2024 Q2	$675K	Buy	17,532 +5,698	+48%	+$240K	0.02%	745
2024 Q1	$507K	Buy	11,834 +1,173	+11%	+$48.4K	0.01%	820
2023 Q4	$395K	Buy	10,661 +971	+10%	+$34.9K	0.01%	887
2023 Q3	$351K	Buy	+9,690	New	+$344K	0.01%	828

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Vident Advisory's GSK Position: Q1 2026 in Review

Vident Advisory increased its GSK (GSK) stake by 32% in Q1 2026, buying an estimated $491K and bringing the position to 36,983 shares worth $2.04M. The position accounts for 0.02% of the portfolio, ranked #620.

Vident Advisory first reported a position in GSK in Q3 2023 and has held it in 11 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Vident Advisory held 36,983 shares of GSK worth $2.04M as of Q1 2026.
Vident Advisory bought 9,064 GSK shares in Q1 2026, an estimated $491K.
GSK made up 0.02% of Vident Advisory's portfolio in Q1 2026, its #620 holding.
Vident Advisory first reported a position in GSK in Q3 2023 and has held it in 11 quarters since.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.